3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Pancreatic Neoplasms
2
Stomach Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Oligometastatic Prostate Cancer
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Bile Duct Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
679
130-nm albumin-bound paclitaxel
198
Fluorouracil
186
Oxaliplatin
175
Albumin-Bound Paclitaxel
151
Capecitabine
137
Leucovorin
131
Irinotecan
113
Radiotherapy
95
Taxes
83
pembrolizumab
80
Cisplatin
72
Erlotinib Hydrochloride
69
Radiosurgery
67
Nivolumab
56
Bevacizumab
54
Drug Therapy
52
Cyclophosphamide
49
Magnetic Resonance Spectroscopy
46
folfirinox
42
Docetaxel
41
Cetuximab
40
Specimen Handling
37
irinotecan sucrosofate
36
S 1 (combination)
36
Biopsy
31
Radiation
29
Paclitaxel
29
Ipilimumab
27
durvalumab
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Neoplasms
×
quemliclustat
×
Clear all
NCT04104672
2026-06-02
ARC-8
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
196 enrolled
NCT06608927
2026-06-02
PRISM-1
Arcus Biosciences, Inc.
Phase 3
Active not recruiting
610 enrolled